STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. I. METHOD FOR THE QUANTITATIVE ASSAY OF SUPPRESSIVE ANTIMALARIAL ACTION IN VIVAX MALARIA

^{Department of Medicine, New York University College of Medicine, New York City}

^{Research Service, Third [New York University] Medical Division, Goldwater Memorial Hospital, New York City}

The work described in this paper was done under a contract, recommended by the Committee on Medical Research, between the Office of Scientific Research and Development and New York University.

A part of the material in this paper has been presented in a Harvey Lecture by Dr. James A. Shannon (1) and also appeared in “Survey of Antimalarial Drugs, 1941-1945,” p. 177, J. W. Edwards, Ann Arbor, Mich., 1946. Permission to use Tables I, II, IV and VI and Figures 1, 2, 3 and 4, has been obtained from the Harvey Society and from the editors of the Survey.

The authors express their thanks to the Malaria Study Section of the National Institute of Health for editorial assistance and for arrangements in regard to the publication of this paper. They are also grateful to the Abbott Laboratories, E. I. du Pont de Nemours and Company, Inc., E. R. Squibb and Sons, Eli Lilly and Company, Sharp and Dohme, and Wyeth, Inc., for contributing toward the publication costs.

Find articles by Shannon, J. in: JCI | PubMed | Google Scholar

^{Department of Medicine, New York University College of Medicine, New York City}

^{Research Service, Third [New York University] Medical Division, Goldwater Memorial Hospital, New York City}

The work described in this paper was done under a contract, recommended by the Committee on Medical Research, between the Office of Scientific Research and Development and New York University.

A part of the material in this paper has been presented in a Harvey Lecture by Dr. James A. Shannon (1) and also appeared in “Survey of Antimalarial Drugs, 1941-1945,” p. 177, J. W. Edwards, Ann Arbor, Mich., 1946. Permission to use Tables I, II, IV and VI and Figures 1, 2, 3 and 4, has been obtained from the Harvey Society and from the editors of the Survey.

The authors express their thanks to the Malaria Study Section of the National Institute of Health for editorial assistance and for arrangements in regard to the publication of this paper. They are also grateful to the Abbott Laboratories, E. I. du Pont de Nemours and Company, Inc., E. R. Squibb and Sons, Eli Lilly and Company, Sharp and Dohme, and Wyeth, Inc., for contributing toward the publication costs.

Find articles by Earle, D. in: JCI | PubMed | Google Scholar

^{Department of Medicine, New York University College of Medicine, New York City}

^{Research Service, Third [New York University] Medical Division, Goldwater Memorial Hospital, New York City}

The work described in this paper was done under a contract, recommended by the Committee on Medical Research, between the Office of Scientific Research and Development and New York University.

A part of the material in this paper has been presented in a Harvey Lecture by Dr. James A. Shannon (1) and also appeared in “Survey of Antimalarial Drugs, 1941-1945,” p. 177, J. W. Edwards, Ann Arbor, Mich., 1946. Permission to use Tables I, II, IV and VI and Figures 1, 2, 3 and 4, has been obtained from the Harvey Society and from the editors of the Survey.

The authors express their thanks to the Malaria Study Section of the National Institute of Health for editorial assistance and for arrangements in regard to the publication of this paper. They are also grateful to the Abbott Laboratories, E. I. du Pont de Nemours and Company, Inc., E. R. Squibb and Sons, Eli Lilly and Company, Sharp and Dohme, and Wyeth, Inc., for contributing toward the publication costs.

Find articles by Berliner, R. in: JCI | PubMed | Google Scholar

^{Department of Medicine, New York University College of Medicine, New York City}

^{Research Service, Third [New York University] Medical Division, Goldwater Memorial Hospital, New York City}

The work described in this paper was done under a contract, recommended by the Committee on Medical Research, between the Office of Scientific Research and Development and New York University.

A part of the material in this paper has been presented in a Harvey Lecture by Dr. James A. Shannon (1) and also appeared in “Survey of Antimalarial Drugs, 1941-1945,” p. 177, J. W. Edwards, Ann Arbor, Mich., 1946. Permission to use Tables I, II, IV and VI and Figures 1, 2, 3 and 4, has been obtained from the Harvey Society and from the editors of the Survey.

The authors express their thanks to the Malaria Study Section of the National Institute of Health for editorial assistance and for arrangements in regard to the publication of this paper. They are also grateful to the Abbott Laboratories, E. I. du Pont de Nemours and Company, Inc., E. R. Squibb and Sons, Eli Lilly and Company, Sharp and Dohme, and Wyeth, Inc., for contributing toward the publication costs.

Find articles by Taggart, J. in: JCI | PubMed | Google Scholar